ReNeuron Group (RENE); provides an update in light of the COVID-19
Following the outbreak of the COVID-19 pandemic, ReNeuron Group initiated a research programme focused on the potential utility of its proprietary exosomes as a delivery vehicle for viral vaccines.
Read more...Cenkos Securities (CNKS); expects to report small profit for FY20
Cenkos, which deferred its results announcement for the year ended 31 December 2019, expects its results to be in line with the trading update issued earlier. It expects to report a small profit for the year. Following the implementation of cost-saving steps introduced, the company expects its annual fixed cost base today to be more than £3.0m lower than in 2019.
Read more...
Fidelity Special Values (FSV); issues 150,000 ordinary shares
Fidelity Special Values has issued a total of 150,000 new ordinary shares of 5p at a price of 172.4p per share. The shares, issued from the company’s block listing facility of 15 January 2019, rank pari passu with the existing ordinary shares in issue.
Read more...John Laing Group (JLG); applies for block listing of 250,000 ordinary shares
John Laing Group has made an application to the UK Listing Authority and the London Stock Exchange (LSE) for a block listing of 250,000 ordinary shares of 10p each. These shares will rank pari passu with the existing issued ordinary shares of the company.
Read more...Ergomed (ERGO); provides update on siltuximab clinical study
Ergomed notes the recent update provided by EUSA Pharma regarding the study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). Recently, EUSA announced initial preliminary findings from the SISCO Study, based on a pre-planned data analysis on 24 March 2020.
Read more...Mercia Asset Management (MERC); direct portfolio companies
Mercia announced that two of its direct portfolio companies, The Native Antigen Company Limited (NAC) and Oxford Genetics Limited (trading as OXGENE), have formed a new strategic partnership to scale up COVID-19 antigen production. Though an important first step, these tests can only detect ongoing COVID-19 infections.
Read more...